Get the Stockscreener App
2.12
2.30%
-0.05
After Hours:
2.13
0.010
+0.47%
Pacific Biosciences Of California Inc stock is traded at $2.12, with a volume of 4.63M.
It is down -2.30% in the last 24 hours and up +21.84% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$2.17
Open:
$2.15
24h Volume:
4.63M
Relative Volume:
0.53
Market Cap:
$640.04M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.4133
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-11.30%
1M Performance:
+21.84%
6M Performance:
+79.66%
1Y Performance:
+3.67%
1-Day Range:
$2.11
$2.19
1-Week Range:
$2.11
$2.48
52-Week Range:
$0.8511
$2.725
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.12 | 655.14M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.3%Here's Why - MarketBeat
Pacific Biosciences accelerates sequencing with HiFi advancements - Traders Union
Aug Swings: How Pacific Biosciences of California Inc stock reacts to Fed rate cutsJuly 2025 Breakouts & Fast Moving Stock Trade Plans - moha.gov.vn
EPS Watch: How Pacific Biosciences of California Inc stock valuations compare to rivalsStop Loss & Reliable Trade Execution Plans - moha.gov.vn
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.8%Should You Sell? - MarketBeat
Pacific Biosciences of California Inc Stock Analysis and ForecastOptions Trading Strategies & Affordable Market Strategies - earlytimes.in
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S Is Still On The Mark Following 26% Share Price Bounce - simplywall.st
Geode Capital Management LLC Increases Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Is Pacific Biosciences of California Inc. stock oversold or undervaluedJuly 2025 Rallies & Safe Swing Trade Setup Alerts - Newser
How Pacific Biosciences of California Inc. (P09) stock reacts to Fed tighteningEarnings Overview Summary & Weekly Top Stock Performers List - Newser
Is Pacific Biosciences of California Inc. (P09) stock undervalued historicallyWeekly Trend Recap & Community Trade Idea Sharing Platform - Newser
Will Pacific Biosciences of California Inc. (P09) stock beat revenue estimates2025 Retail Activity & Long-Term Safe Investment Plans - Newser
Why PacBio (PACB) Stock Is Up Today - Yahoo Finance
Pacific Biosciences (PACB) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Pacific Biosciences of California advances RNA sequencing in lung cancer research - Traders Union
Buy Signal: Will Pacific Biosciences of California Inc stock maintain dividend yieldJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - BỘ NỘI VỤ
Does Pacific Biosciences of California Inc. (P09) stock trade below intrinsic valueMarket Risk Summary & Fast Moving Market Watchlists - Newser
Why Pacific Biosciences of California Inc. (P09) stock remains top rated2025 Earnings Impact & Fast Moving Trade Plans - Newser
How higher bond yields impact Pacific Biosciences of California Inc. (P09) stockJuly 2025 Market Mood & Safe Swing Trade Setups - Newser
XTX Topco Ltd Has $1.18 Million Stock Holdings in Pacific Biosciences of California, Inc. $PACB - MarketBeat
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference - marketscreener.com
PacBio (NASDAQ: PACB) schedules fireside chat at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Is Pacific Biosciences of California Inc. stock safe for conservative investorsMarket Activity Summary & Low Drawdown Investment Strategies - moha.gov.vn
How Recent Moves Are Rewriting the Story for PacBio Amid Shifting Analyst Sentiment - Yahoo Finance
Pacific Biosciences of California Insiders Made A Wise Decision By Selling US$864k Worth Of Stock - simplywall.st
Pullback Watch: Is Pacific Biosciences of California Inc. stock cheap compared to fundamentalsPortfolio Value Report & Real-Time Stock Entry Alerts - moha.gov.vn
Pacific Biosciences of California, Inc.Common Stock (NQ: PACB - Markets Financial Content
How risky is Pacific Biosciences of California Inc. stock now2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
PACB Shares Climb as Market Adjusts to New Forecasts - timothysykes.com
Pacific Biosciences of California, Inc. $PACB Shares Sold by Edmond DE Rothschild Holding S.A. - MarketBeat
Pacific Biosciences of California: HiFi sequencing resolves genome complexities - Traders Union
Pacific Biosciences stock delivers 70% return after InvestingPro’s undervalued call By Investing.com - Investing.com Australia
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - Finviz
PacBio Gains Traction with New Sequel II CNDx Approval in China - StocksToTrade
PacBio’s Strategic Steps: China’s Approval and HiFi Sequencing Insights Boost Confidence - timothysykes.com
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
What analysts say about Pacific Biosciences of California Inc P09 stockRetail Trading Trends & Low Entry Cost Capital - earlytimes.in
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
What analysts say about Pacific Biosciences of California Inc stock - earlytimes.in
Can Dev Information Technology Limited Outperform Peers After Recent PullbackMarket Depth Overview & Low Risk Investment Tips - earlytimes.in
PacBio Stock Soars: Time to Dive In? - StocksToTrade
Pacific Biosciences of California launches HiFi guide to enhance lab workflows - Traders Union
PacBio’s Regulatory Triumph in China Fuels Market Optimism - timothysykes.com
$PACB stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
PacBio’s New Regulatory Approval Fuels Expansion Hopes - timothysykes.com
Pacific Biosciences partners with SPT Labtech to enhance automation - Traders Union
Will Pacific Biosciences of California Inc. stock split again soon2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):